NASDAQ · AVR
Anteris Technologies Global Corp.
$6.42+$0.32 (+5.25%)
Anteris Technologies Global Corp.’s quoted price sits in the lower half of its reported 52-week range, 41.95% below the high.
Loading market information…
NASDAQ · ARAY · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Accuray Incorporated’s quoted price sits in the lower half of its reported 52-week range, 90.41% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Accuray Incorporated’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Accuray Incorporated’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2025 | Apr 30, 2025 | -$0.01+80.0% vs estimate | $113.24M-8.51% vs estimate |
|---|
| Q2 2025 | Feb 5, 2025 | $0.02+300.0% vs estimate | $116.17M+5.27% vs estimate |
|---|
| Q1 2025 | Nov 6, 2024 | -$0.04-24.53% vs estimate | $101.55M+4.1% vs estimate |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$6.42+$0.32 (+5.25%)
Anteris Technologies Global Corp.’s quoted price sits in the lower half of its reported 52-week range, 41.95% below the high.
$21.79+$0.24 (+1.11%)
Anika Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.76% below the high.
$3.86-$0.07 (-1.78%)
TriSalus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.45% below the high.
$5.86+$0.08 (+1.38%)
Profound Medical Corp.’s quoted price sits in the lower half of its reported 52-week range, 34.53% below the high.
$1.73+$0.02 (+1.17%)
MaxCyte, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.42% below the high.
$4.19+$0.02 (+0.48%)
Owlet, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.27% below the high.
$0.79+$0.03 (+4.25%)
Milestone Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.2% below the high.
$5.97+$0.05 (+0.84%)
LENSAR Inc’s quoted price sits in the lower half of its reported 52-week range, 53.86% below the high.
